How Does Glucagon Work? Mechanism of Action, Per the Research

Glucagon is a 29-amino-acid peptide hormone released by pancreatic alpha cells and cleaved from the proglucagon precursor. It is also a prescription medicine, used under clinical supervision, and is not a consumer supplement. This page summarises what the published pharmacology literature describes about its receptor targets, intracellular signalling and downstream physiology, and separates mechanisms that are well established from mechanisms still described as proposed or preclinical. For broader background, see the PeptideU glucagon overview.

The receptor: GCGR, a class B G-protein-coupled receptor

The glucagon receptor (GCGR) belongs to the class B (secretin-like) family of G-protein-coupled receptors, the same structural family that includes receptors for GLP-1, GIP and secretin. A 2024 Physiological Reviews synthesis of hepatic glucagon action reported that GCGR is expressed most densely on hepatocytes and that hepatic receptor engagement accounts for the hormone's canonical metabolic effects (PMID 38300523). A 2023 centenary review in Diabetologia traced the same receptor biology from glucagon's discovery through contemporary alpha-cell physiology and described how receptor-level understanding reframed glucagon from a simple "counter-regulatory" hormone into a broader metabolic regulator (PMID 37367959).

The signalling sequence described in these reviews follows the classic class B pattern: the peptide's N-terminus inserts into the receptor's transmembrane core, the receptor couples to the stimulatory G protein Gs, adenylyl cyclase is activated, intracellular cyclic AMP (cAMP) rises, and protein kinase A (PKA) phosphorylates downstream enzymes and transcriptional regulators. The 2024 hepatic review described this cAMP/PKA axis as the dominant route through which glucagon reshapes hepatocyte metabolism, with additional calcium-dependent and beta-arrestin-linked signalling branches reported as context-dependent (PMID 38300523).

Established mechanism: what the literature describes in the liver

Glycogen breakdown and gluconeogenesis

The best-characterised consequence of GCGR activation is mobilisation of hepatic glucose. The 2024 Physiological Reviews paper reported that PKA-driven phosphorylation cascades activate glycogen phosphorylase and inhibit glycogen synthase, releasing glucose from stored glycogen, while transcriptional and allosteric changes simultaneously push gluconeogenic flux from lactate, glycerol and amino acid substrates (PMID 38300523). The 2023 historical review described this glucose-raising action as the property that defined glucagon for its first several decades and that underpins its clinical identity as a counter-regulatory hormone opposing insulin (PMID 37367959).

Amino acid catabolism and the liver–alpha cell axis

A major theme of the modern literature is that glucose is only part of the picture. The 2024 hepatic review described glucagon as a strong driver of hepatic amino acid uptake, catabolism and ureagenesis, and summarised the "liver–alpha cell axis" in which circulating amino acids feed back to stimulate alpha-cell glucagon secretion and alpha-cell mass (PMID 38300523). The centenary review reported that this feedback loop reframed hyperglucagonaemia in metabolic liver disease as a possible consequence of impaired hepatic glucagon signalling rather than purely an alpha-cell defect (PMID 37367959).

Lipid handling in the hepatocyte

Researchers have also described hepatic lipid effects downstream of GCGR. The 2024 review reported that glucagon signalling increases fatty acid oxidation and influences hepatic lipid export and triglyceride content, effects it grouped under actions "beyond glucose mobilization" (PMID 38300523). A 2024 Advanced Science study in cells and mice reported that the tetraspanin CD9 counteracted liver steatosis and was required for the hepatic effects of a GCGR agonist, identifying a molecular intermediary between receptor activation and lipid phenotype (PMID 38837628); that work was preclinical and has not been shown to translate to humans.

Signalling map as described in the literature

Beyond the liver: energy expenditure and systemic signalling

A 2025 Journal of Hepatology study reported that glucagon controlled an obesity-specific component of energy expenditure through persistent hepatic cAMP/PKA signalling, distinguishing sustained from transient receptor signalling as a determinant of the metabolic readout (PMID 40550339). The study was mechanistic and preclinical; it described a signalling property, not a therapeutic outcome. The 2023 centenary review placed such findings in the context of glucagon's energy-expenditure actions being a reason investigators built dual and triple incretin–glucagon receptor co-agonists, while noting that those agents are distinct molecules with their own evidence base (PMID 37367959).

Glucagon also sits within a wider enteropancreatic signalling network. A 2021 review of hunger and satiety signalling in the gastrointestinal tract described how proglucagon-derived peptides and other gut hormones relay nutrient status to the brain and influence appetite-related pathways (PMID 34153172). That review discussed signalling architecture across the gut–brain axis rather than establishing glucagon-specific appetite effects in people.

Proposed and preclinical mechanisms

Several strands of recent work are explicitly exploratory and should be read as hypothesis-generating rather than established human pharmacology.

• An upstream hormonal regulator. A 2025 Cell Metabolism report described a famsin–glucagon axis mediating glucose homeostasis, positioning famsin as a fasting-associated signal acting upstream of glucagon in animal models (PMID 39706194).
• Constitutive receptor activity. A 2025 Nature paper reported that a constitutively active glucagon receptor drove high blood glucose in birds, using comparative physiology to show how intrinsic receptor activity — signalling without ligand — can set baseline glycaemia (PMID 40031956). The finding concerns avian biology and was not a human study.
• Receptor blockade as a probe. A 2024 Circulation Research study evaluated a glucagon receptor antagonist in heart failure with preserved ejection fraction, using pharmacological blockade to interrogate GCGR's contribution to cardiometabolic phenotypes (PMID 39011638). Antagonist work informs mechanism; it does not describe how glucagon itself is used clinically.
• Autophagy. A 2025 Current Opinion in Cell Biology review summarised how upstream signalling pathways regulate autophagy, the nutrient-responsive degradation programme that hepatic fasting hormones are proposed to engage (PMID 41086756). This remains a proposed rather than settled component of glucagon's downstream physiology.

Why glucagon is not GLP-1

Glucagon and GLP-1 are both cleaved from proglucagon, but they act at different class B receptors with different downstream physiology, and literature about one does not transfer to the other. A 2024 Cardiovascular Research study reported that GLP-1 increased heart rate through a direct action on the sinus node, an effect attributed to GLP-1 receptor signalling in cardiac pacemaker tissue (PMID 38832935). A 2022 British Journal of Pharmacology review described GLP-1 receptor agonists modulating reward-related circuitry in preclinical models of addictive disorders (PMID 34532853), and a 2019 study in Journal of Cachexia, Sarcopenia and Muscle reported that a GLP-1 receptor agonist ameliorated muscle wasting in an animal model of muscle atrophy (PMID 31020810). Those are GLP-1 receptor findings; the 2023 centenary review emphasised that glucagon's own receptor pharmacology is distinct and has its own, separate evidence base (PMID 37367959).

Established versus proposed: how the literature divides

Tolerability and Safety Signals: What Studies Report

The papers summarised on this page were mechanistic reviews and preclinical investigations rather than tolerability trials, so they do not provide an adverse-event profile for glucagon as a medicine. The 2023 centenary review in Diabetologia discussed glucagon's therapeutic history and the practical considerations that shaped its clinical formulations, but detailed safety characterisation sits in regulatory product labelling and clinical trial reporting rather than in mechanism papers (PMID 37367959). Similarly, the 2024 Circulation Research work used receptor antagonism as an experimental tool in a disease model and did not characterise human safety of glucagon itself (PMID 39011638). Questions about contraindications, interactions or monitoring belong with a prescribing clinician and the approved product information.

Regulatory and clinical context

Glucagon is a regulated prescription medicine with approved formulations; it is prescribed, dispensed and administered within clinical pathways. Nothing on this page describes how, when or whether glucagon should be used, and no doses are stated. The 2023 review noted that a century of research shifted glucagon's framing from a single-purpose counter-regulatory hormone to a target for receptor agonists and antagonists under investigation, with those investigational agents carrying regulatory status separate from glucagon itself (PMID 37367959).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Readers evaluating what the cited literature means for an individual situation should raise it with a prescribing clinician, who can weigh the evidence against that person's history.

References

• Hepatic glucagon action: beyond glucose mobilization (Physiological Reviews, 2024)
• 100 years of glucagon and 100 more (Diabetologia, 2023)
• The gastrointestinal tract in hunger and satiety signalling (United European Gastroenterology Journal, 2021)
• The role of glucagon-like peptide 1 (GLP-1) in addictive disorders (British Journal of Pharmacology, 2022)
• A famsin-glucagon axis mediates glucose homeostasis (Cell Metabolism, 2025)
• Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction (Circulation Research, 2024)
• Constitutively active glucagon receptor drives high blood glucose in birds (Nature, 2025)
• Autophagy regulation by signaling (Current Opinion in Cell Biology, 2025)
• Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy (Journal of Cachexia, Sarcopenia and Muscle, 2019)
• CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects (Advanced Science, 2024)
• Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node (Cardiovascular Research, 2024)
• Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling (Journal of Hepatology, 2025)